Xiaosu Zhao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1316793/publications.pdf

Version: 2024-02-01

551 papers	14,136 citations	36691 53 h-index	51423 90 g-index
614 all docs	614 docs citations	614 times ranked	9236 citing authors

#	Article	IF	Citations
1	Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia. Journal of Cancer Research and Clinical Oncology, 2022, 148, 449-459.	1.2	3
2	Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia, 2022, 36, 267-270.	3.3	14
3	Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?. Leukemia, 2022, 36, 482-491.	3.3	17
4	Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation. Acta Haematologica, 2022, 145, 54-62.	0.7	6
5	Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. British Journal of Haematology, 2022, 196, 735-742.	1.2	3
6	Medication therapy of highâ€dose methotrexate: An evidenceâ€based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. British Journal of Clinical Pharmacology, 2022, 88, 2456-2472.	1.1	9
7	Donor activating killer cell immunoglobulinâ€like receptors genes correlated with Epsteinâ€“Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2022, 196, 1007-1017.	1.2	4
8	Preemptive Interferon-Î± Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Frontiers in Immunology, 2022, 13, 757002.	2.2	13
9	Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation. International Journal of Laboratory Hematology, 2022, 44, 510-517.	0.7	3
10	Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. Bone Marrow Transplantation, 2022, , .	1.3	5
11	The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 535-544.	0.2	6
12	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2022, 22, 11.	1.1	2
13	Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation. Therapeutic Advances in Hematology, 2022, 13, 204062072110728.	1.1	8
14	Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cellular and Molecular Immunology, 2022, 19, 482-491.	4.8	15
15	Basiliximab for steroidâ€refractory acute graftâ€versusâ€host disease: A realâ€world analysis. American Journal of Hematology, 2022, 97, 458-469.	2.0	19
16	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplantation, 2022, 57, 572-578.	1.3	4
17	Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia. Blood Science, 2022, 4, 16-28.	0.4	8
18	Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis Bâ€related cirrhosis: Multicentre realâ€world observational study. Journal of Viral Hepatitis, 2022, 29, 306-316.	1.0	4

#	Article	IF	Citations
19	A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia, 2022, 36, 1336-1342.	3.3	11
20	Recipient and donor PTX3 rs2305619 polymorphisms increase the susceptibility to invasive fungal disease following haploidentical stem cell transplantation: a prospective study. BMC Infectious Diseases, 2022, 22, 292.	1.3	2
21	Adoptive therapy with <scp>cytomegalovirus</scp>â€specific T cells for <scp>cytomegalovirus</scp> infection after haploidentical stem cell transplantation and factors affecting efficacy. American Journal of Hematology, 2022, 97, 762-769.	2.0	14
22	A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2022, 12, 862526.	1.8	7
23	The glycolytic enzyme PFKFB3 determines bone marrow endothelial progenitor cell damage after chemotherapy and irradiation. Haematologica, 2022, 107, 2365-2380.	1.7	8
24	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression. Journal of Immunology, 2022, 208, 492-500.	0.4	5
25	Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes. Journal of Translational Medicine, 2022, 20, 144.	1.8	3
26	Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study. Therapeutic Advances in Hematology, 2022, 13, 204062072210952.	1.1	5
27	The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 814334.	2.2	3
28	Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial. BMC Medicine, 2022, 20, 140.	2.3	8
29	A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Experimental Hematology and Oncology, 2022, 11, 25.	2.0	19
30	Independent prognostic significance of <scp>TP53</scp> mutations in adult acute myeloid leukaemia with complex karyotype. International Journal of Laboratory Hematology, 2022, , .	0.7	4
31	Combination of KIT and FLT3â€ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. Hematological Oncology, 2022, 40, 724-733.	0.8	2
32	Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. Bone Marrow Transplantation, 2022, 57, 1204-1206.	1.3	5
33	Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase. Leukemia, 2022, 36, 1818-1824.	3.3	6
34	Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First-in-human Phase I Clinical Trial. Blood, 2022, , .	0.6	36
35	CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clinical and Experimental Immunology, 2022, 208, 332-339.	1.1	6
36	Multiomics Analysis Identifies SOCS1 as Restraining T Cell Activation and Preventing Graftâ€Versusâ€Host Disease. Advanced Science, 2022, 9, e2200978.	5.6	7

#	Article	IF	Citations
37	An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood, 2022, 140, 516-520.	0.6	18
38	Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy. Leukemia, 2022, 36, 2042-2049.	3.3	4
39	The impact of pretransplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents. Pediatric Blood and Cancer, 2022, 69, .	0.8	1
40	Prognostic value of postâ€transplantation Wilms' tumor gene 1 expression in acute myeloid leukaemia subgroup according to different preâ€transplant disease status. International Journal of Laboratory Hematology, 2022, 44, .	0.7	0
41	The loss or absence of minimal residual disease of <0Â·1% at any time after two cycles of consolidation chemotherapy in CBFBâ€“MYH11â€positive acute myeloid leukaemia indicates poor prognosis. British Journal of Haematology, 2021, 192, 265-271.	1.2	13
42	Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. Annals of Hematology, 2021, 100, 169-180.	0.8	14
43	Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1469-1479.	1.2	8
44	Ethnic and geographic diversity of chronic lymphocytic leukaemia. Leukemia, 2021, 35, 433-439.	3.3	21
45	The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clinical Transplantation, 2021, 35, e14160.	0.8	12
46	Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges. Bone Marrow Transplantation, 2021, 56, 779-785.	1.3	23
47	Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia. Science China Life Sciences, 2021, 64, 766-783.	2.3	10
48	Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. Annals of Hematology, 2021, 100, 799-808.	0.8	2
49	Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graftâ€versusâ€host disease. Transplant Infectious Disease, 2021, 23, e13544.	0.7	5
50	Cellular immunotherapy for hematological malignancy: recent progress and future perspectives. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	6
51	Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Annals of Hematology, 2021, 100, 505-516.	0.8	4
52	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. Annals of Hematology, 2021, 100, 1203-1212.	0.8	10
53	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	31
54	Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation Compared With Chemotherapy as Postremission Treatment of Children With Intermediate-risk Acute Myeloid Leukemia in First Complete Remission. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e126-e136.	0.2	5

#	Article	IF	Citations
55	Preâ€transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. Cancer Communications, 2021, 41, 333-344.	3.7	5
56	Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. Frontiers in Oncology, 2021, 11, 639502.	1.3	4
57	HCMV modulates câ€Mpl/IEXâ€1 pathwayâ€mediated megakaryo/thrombopoiesis via PDGFRÎ± and Î±vÎ²3 receptors after alloâ€HSCT. Journal of Cellular Physiology, 2021, 236, 6726-6741.	2.0	1
58	Wilmsâ€™ tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. BMC Cancer, 2021, 21, 292.	1.1	5
59	Overcoming graft failure after haploidentical transplantation: Is this a possibility?. Best Practice and Research in Clinical Haematology, 2021, 34, 101255.	0.7	5
60	A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation. Chinese Medical Journal, 2021, 134, 1199-1208.	0.9	3
61	G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study. Frontiers in Oncology, 2021, 11, 631625.	1.3	8
62	Acute Cholecystitis Following Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Features, Outcomes, Risk Factors, and Prediction Model. Transplantation and Cellular Therapy, 2021, 27, 253.e1-253.e9.	0.6	1
63	The Prognostic Significance of ZNF384 Fusions in Adult Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: A Comprehensive Cohort Study From a Single Chinese Center. Frontiers in Oncology, 2021, 11, 632532.	1.3	9
64	Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. American Journal of Hematology, 2021, 96, 561-570.	2.0	5
65	Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2021, 100, 1267-1281.	0.8	3
66	Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2097-2107.	1.3	9
67	Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study. Transplant Infectious Disease, 2021, 23, e13611.	0.7	7
68	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. Leukemia, 2021, 35, 3092-3100.	3.3	22
69	The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 67.	2.8	9
70	Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings. Expert Review of Hematology, 2021, 14, 449-455.	1.0	5
71	Potential Applications in Sewage Bioremediation of the Highly Efficient Pyridine-Transforming Paenochrobactrum sp.. Applied Biochemistry and Microbiology, 2021, 57, 344-350.	0.3	2
72	Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia. Current Medical Science, 2021, 41, 443-453.	0.7	3

#	Article	IF	Citations
73	Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Science Bulletin, 2021, 66, 2498-2505.	4.3	44
74	Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?. Journal of Clinical Medicine, 2021, 10, 2516.	1.0	0
75	Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. Frontiers in Medicine, 2021, 8, 604085.	1.2	13
76	M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity. Signal Transduction and Targeted Therapy, 2021, 6, 234.	7.1	37
77	Î³Î´ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation. Frontiers in Immunology, 2021, 12, 687961.	2.2	5
78	Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients. Medicine (United States), 2021, 100, e26772.	0.4	4
79	Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion. Frontiers of Medicine, 2021, 15, 728-739.	1.5	0
80	Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. Bone Marrow Transplantation, 2021, 56, 2723-2731.	1.3	4
81	Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. Annals of Hematology, 2021, 100, 2557-2566.	0.8	4
82	Interferon-Î± as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 2949-2956.	0.6	14
83	Improved function and balance in T cell modulation by endothelial cells in young people. Clinical and Experimental Immunology, 2021, 206, 196-207.	1.1	4
84	Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model. Frontiers in Oncology, 2021, 11, 706935.	1.3	3
85	PMLâ€RARA transcript levels at the end of induction therapy are associated with prognosis in nonâ€highâ€risk acute promyelocytic leukaemia with allâ€•trans retinoic acid plus arsenic in frontâ€line therapy: longâ€term followâ€up of a singleâ€centre cohort study. British Journal of Haematology, 2021, 195, 722-730.	1.2	3
86	Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 668.e1-668.e9.	0.6	3
87	Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplantation, 2021, 56, 2940-2947.	1.3	43
88	Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation. Blood Advances, 2021, 5, 4910-4921.	2.5	4
89	Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. American Journal of Hematology, 2021, 96, 1407-1419.	2.0	5
90	Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells. Blood Reviews, 2021, 51, 100884.	2.8	1

#	Article	IF	Citations
91	Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease. Frontiers in Immunology, 2021, 12, 749266.	2.2	12
92	Targeting IFN-Î³-inducible lysosomal thiol reductase overcomes chemoresistance in AML through regulating the ROS-mediated mitochondrial damage. Translational Oncology, 2021, 14, 101159.	1.7	5
93	The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2021, 12, 720354.	2.2	14
94	The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. Journal of Hematology and Oncology, 2021, 14, 145.	6.9	124
95	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e699-e709.	0.2	19
96	A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Advances, 2021, 5, 5479-5489.	2.5	6
97	All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematology,the, 2021, 8, e688-e699.	2.2	19
98	Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models. Bone Marrow Transplantation, 2021, 56, 1341-1351.	1.3	8
99	Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. Annals of Hematology, 2021, 100, 555-562.	0.8	5
100	Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cellular and Molecular Immunology, 2021, 18, 1172-1185.	4.8	55
101	A modified conditioning regimen based on lowâ€dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity. Clinical Transplantation, 2021, , e14514.	0.8	3
102	A case of iron deficiency anemia with extremely hyperferritinemia responds well to oral iron: the first identified hereditary hyperferritinemia cataract syndrome in China. Annals of Hematology, 2021, 100, 2407-2410.	0.8	0
103	Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective. Frontiers in Oncology, 2021, 11, 758512.	1.3	11
104	Optimizing Allogeneic Grafts in Hematopoietic Stem Cell Transplantation. Stem Cells Translational Medicine, 2021, 10, S41-S47.	1.6	9
105	Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia. Hematology, 2021, 26, 9-15.	0.7	0
106	All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood, 2021, , .	0.6	10
107	PRDM1 Is Sufficient for Inducing Human Primary T Cell Hyporesponsiveness and Implicates Low Gvhd Occurrence after Allo-HSCT. Blood, 2021, 138, 197-197.	0.6	1
108	Treatment Outcome and Efficacy of Therapeutic Plasma Exchange for Transplant-Associated Thrombotic Microangiopathy in a Real-World Large Cohort Study. Blood, 2021, 138, 1013-1013.	0.6	0

#	Article	IF	Citations
109	Sex Differences in EBV Viremia after Haplo-HSCT Imply Sex Bias during Immune Reconstitution. Blood, 2021, 138, 2886-2886.	0.6	0
110	Detection of CSRP2 Transcript Levels By Real-Time Quantitative PCR May be a Useful Tool for Monitoring Minimal Residual Disease in B-Cell ALL. Blood, 2021, 138, 3998-3998.	0.6	0
111	A Predictive Score for Failure-Free Survival in Persons with Chronic Myeloid Leukemia Receiving Imatinib. Blood, 2021, 138, 632-632.	0.6	0
112	Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Phâ˜ high-risk B-cell acute lymphoblastic leukemia. Chinese Medical Journal, 2021, Publish Ahead of Print, .	0.9	4
113	A Predictive Score for Outcomes of Tyrosine Kinase-Inhibitor Therapy in Persons with Chronic Myeloid Leukaemia Presenting in Accelerated Phase. Blood, 2021, 138, 636-636.	0.6	0
114	Comparison of Transplant Donor and Third-Party Donor Derived CMV-Specific T Cells for CMV Infection after Allogenic Stem Cell Transplantation. Blood, 2021, 138, 1701-1701.	0.6	0
115	Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET) Tj ETQq1 1 0.784314 rgBT /Ov	0.6	8
116	Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP). Blood, 2021, 138, 3598-3598.	0.6	9
117	Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. Frontiers in Immunology, 2021, 12, 731435.	2.2	4
118	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Oncology, 2021, 11, 773394.	1.3	8
119	First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)â€“specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 70, 1429-1437.	2.9	30
120	NK cell reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with matched sibling transplantation. Science China Life Sciences, 2020, 63, 781-784.	2.3	5
121	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 12-24.	1.3	94
122	Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). Science China Life Sciences, 2020, 63, 571-581.	2.3	26
123	The Quantification of Minimal Residual Disease Preâ€•and Postâ€Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 75-87.	0.7	18
124	Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation. Science China Life Sciences, 2020, 63, 138-147.	2.3	4
125	Haploidentical hematopoietic cell transplantation for severe acquired aplastic anemia: a case-control study of post-transplant cyclophosphamide included regimen vs. anti-thymocyte globulin & colony-stimulating factor-based regimen. Science China Life Sciences, 2020, 63, 940-942.	2.3	15
126	Improved survival after offspring donor transplant compared with older agedâ€•matched siblings for older leukaemia patients. British Journal of Haematology, 2020, 189, 153-161.	1.2	8

#	Article	IF	Citations
127	Basiliximab as Treatment for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 351-357.	2.0	20
128	The prognostic significance of Î”SUVmax assessed by PET/CT scan after 2 cycles of chemotherapy in patients with classic Hodgkinâ€™s lymphoma. Annals of Hematology, 2020, 99, 293-299.	0.8	3
129	Myeloid Neoplasms with Elevated Plasmacytoid Dendritic Cell Differentiation Reflect the Maturation Process of Dendritic Cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 61-69.	1.1	17
130	Incidence, Risk Factors, Outcomes, and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1171-1178.	2.0	8
131	Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as postâ€remission treatment for children with very highâ€risk philadelphia chromosome negative Bâ€cell acute lymphoblastic leukaemia in first complete remission. British Journal of Haematology, 2020, 188, 757-767.	1.2	17
132	Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia, 2020, 34, 1433-1443.	3.3	73
133	Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2020, 22, 188-195.	1.2	4
134	The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia. Annals of Hematology, 2020, 99, 73-82.	0.8	15
135	Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome. Pediatric Transplantation, 2020, 24, e13864.	0.5	5
136	Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2020, 22, 755-761.	0.3	33
137	Therapeutic Approaches for Acute Promyelocytic Leukaemia: Moving Towards an Orally Chemotherapy-Free Era. Frontiers in Oncology, 2020, 10, 586004.	1.3	7
138	Preemptive interferon-Î± treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. Scientific Reports, 2020, 10, 20148.	1.6	7
139	Valproic acid enhances pamidronate-sensitized cytotoxicity of VÎ´2+ T cells against EBV-related lymphoproliferative cells. International Immunopharmacology, 2020, 88, 106890.	1.7	2
140	Reply to M. Shibusawa et al. Journal of Clinical Oncology, 2020, 38, 4224-4225.	0.8	0
141	Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncology, The, 2020, 21, 1201-1212.	5.1	209
142	The incidence, risk factors, and outcomes of acute graftâ€vsâ€host disease in pediatric Tâ€cellâ€replete haploidentical hematopoietic stem cell transplantation. Pediatric Transplantation, 2020, 24, e13793.	0.5	1
143	Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia. Molecular Therapy - Oncolytics, 2020, 18, 272-281.	2.0	68
144	Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2659-2670.	0.8	13

#	Article	IF	Citations
145	Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor. Biology of Blood and Marrow Transplantation, 2020, 26, 1655-1662.	2.0	8
146	Production of lentiviral vectors in suspension cells using low proportion of supercoiled circular plasmid DNA. Cytotechnology, 2020, 72, 897-905.	0.7	0
147	Th2 polarization in target organs is involved in the alleviation of pathological damage mediated by transplanting granulocyte colony-stimulating factor-primed donor T cells. Science China Life Sciences, 2020, 64, 1087-1096.	2.3	4
148	A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Advances, 2020, 4, 5846-5857.	2.5	5
149	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. Journal of Hematology and Oncology, 2020, 13, 52.	6.9	13
150	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 2087-2097.	1.3	8
151	Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. Science China Life Sciences, 2020, 63, 1744-1754.	2.3	14
152	Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplantation, 2020, 55, 2035-2042.	1.3	11
153	Development and validation of a prediction model (AHC) for early identification of refractory thrombotic thrombocytopenic purpura using nationally representative data. British Journal of Haematology, 2020, 191, 269-281.	1.2	5
154	miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. Molecular Therapy - Nucleic Acids, 2020, 20, 764-776.	2.3	28
155	Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene. Expert Review of Anticancer Therapy, 2020, 20, 453-464.	1.1	7
156	Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. BMC Cancer, 2020, 20, 553.	1.1	21
157	Haploidenticalâ€•versus identicalâ€sibling transplant for highâ€risk pediatric AML: A multiâ€center study. Cancer Communications, 2020, 40, 93-104.	3.7	20
158	Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. Journal of Hematology and Oncology, 2020, 13, 18.	6.9	36
159	CD8+CD161hi T cells are associated with acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1652-1654.	1.3	3
160	Monocyte subsets in bone marrow grafts may contribute to a low incidence of acute graftâ€vsâ€host disease for young donors. Journal of Cellular and Molecular Medicine, 2020, 24, 9204-9216.	1.6	2
161	Serum Lactate Dehydrogenase Can Be Used as a Factor for Re-Evaluating First-Relapsed Multiple Myeloma. Acta Haematologica, 2020, 143, 559-566.	0.7	10
162	Outcomes of symptomatic venous thromboembolism after haploidentical donor hematopoietic stem cell transplantation and comparison with human leukocyte antigen-identical sibling transplantation. Thrombosis Research, 2020, 194, 168-175.	0.8	2

#	Article	IF	Citations
163	Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 1833-1843.	0.8	3
164	Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. Journal of Clinical Oncology, 2020, 38, 3367-3376.	0.8	69
165	Activated inducible co-stimulator-positive programmed cell death 1-positive follicular helper T cells indicate disease activity and severity in ulcerative colitis patients. Clinical and Experimental Immunology, 2020, 202, 106-118.	1.1	10
166	Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplantation, 2020, 55, 1068-1075.	1.3	9
167	Detection of measurable residual disease may better predict outcomes than mutations based on nextâ€generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. British Journal of Haematology, 2020, 190, 533-544.	1.2	14
168	Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fmsâ€like tyrosine kinase 3 internal tandem duplication (FLT3â€ITD). British Journal of Haematology, 2020, 190, 274-283.	1.2	18
169	DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 190, 67-78.	1.2	11
170	Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia Research, 2020, 91, 106333.	0.4	11
171	Haploidentical stem cell transplantation in patients with chronic myelomonocytic leukemia. Science China Life Sciences, 2020, 63, 1261-1264.	2.3	8
172	Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study. Science China Life Sciences, 2020, 63, 1552-1564.	2.3	12
173	Frequency, Risk Factors, and Outcome of Active Tuberculosis following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1203-1209.	2.0	9
174	Autophagy in endothelial cells regulates their haematopoiesis-supporting ability. EBioMedicine, 2020, 53, 102677.	2.7	13
175	Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e304-e315.	0.2	6
176	Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: A retrospective multicenter cohort study. Clinical Transplantation, 2020, 34, e13810.	0.8	16
177	Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1147-1160.	1.3	18
178	Fluorescence in situ hybridisation combined with CD138 immunomagnetic sorting is effective to identify cytogenetic abnormalities which play significant prognostic roles in Chinese AL amyloidosis patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 208-209.	1.4	3
179	Expanded clinicalâ€grade membraneâ€bound ILâ€21/4â€1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. European Journal of Immunology, 2020, 50, 1374-1385.	1.6	22
180	Incidence, Risk Factors, and Outcomes of Primary Prolonged Isolated Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, 1452-1458.	2.0	10

#	Article	IF	Citations
181	A retrospective analysis on anti-CD20 antibodyâ€“treated Epsteinâ€“Barr virusâ€“related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2649-2657.	0.8	2
182	Staged horizontal bone augmentation for dental implants in aesthetic zones: A prospective randomized controlled clinical trial comparing a half-columnar bone block harvested from the ramus versus a rectangular bone block from the symphysis. International Journal of Oral and Maxillofacial Surgery, 2020, 49, 1326-1334.	0.7	8
183	Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia, 2020, 34, 1229-1240.	3.3	73
184	Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting VÎ´2+T cells activities after hematopoietic transplantation for blood malignancies. , 2020, 8, e000208.		18
185	Osteoclast stimulatory transmembrane protein (OCâ€STAMP) is a promising molecular prognostic indicator for multiple myeloma. European Journal of Haematology, 2020, 105, 185-195.	1.1	2
186	Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia. Annals of Hematology, 2020, 99, 2703-2704.	0.8	0
187	Prognostic factors and longâ€term followâ€up of basiliximab for steroidâ€refractory acute <scp>graftâ€versusâ€host disease</scp>: Updated experience from a largeâ€scale study. American Journal of Hematology, 2020, 95, 927-936.	2.0	32
188	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. Journal of Hematology and Oncology, 2020, 13, 27.	6.9	48
189	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica, 2020, 105, 47-58.	1.7	51
190	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. Frontiers in Oncology, 2020, 10, 320.	1.3	17
191	Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 620891.	2.2	21
192	Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. Annals of Hematology, 2020, 99, 1643-1653.	0.8	3
193	Prognostic significance of SET-NUP214 fusion gene in acute leukemia after allogeneic hematopoietic stem cell transplantation. Medicine (United States), 2020, 99, e23569.	0.4	6
194	Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials. Blood, 2020, 136, 50-51.	0.6	18
195	Long-Term Follow-up of a Randomized Trial of Two Dose Levels of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 20-20.	0.6	7
196	MEKK3 Regulates Angiogenesis through Smad Signaling. Blood, 2020, 136, 7-7.	0.6	0
197	M2 Macrophages, but Not M1 Macrophages, Support Megakaryopoiesis Via up-Regulating PI3K-AKT Pathway. Blood, 2020, 136, 1-1.	0.6	0
198	Induced CD25+CD127dim Î“Î´ Tregs in Acute Myeloid Leukemia Suppress the Activity of Normal ÎÎ² T Cells. Blood, 2020, 136, 27-28.	0.6	0

#	Article	IF	Citations
199	M1 and M2 Macrophages Play Different Roles in the Pathogenesis of Acute Graft-Versus-Host Disease Post-Allotransplant By Modulating Immune Microenvironment. Blood, 2020, 136, 19-20.	0.6	0
200	Development and Validation of a Prognostic Model for Transplant-Associated Thrombotic Microangiopathy Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 16-17.	0.6	0
201	Fluconazole is as effective as other anti-mold agents in preventing early invasive fungal disease after allogeneic stem cell transplantation: assessment of antifungal therapy in haematological disease in China. Translational Cancer Research, 2020, 9, 6900-6911.	0.4	0
202	Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor. Blood, 2020, 136, 38-41.	0.6	0
203	Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children. Science China Life Sciences, 2019, 62, 104-111.	2.3	6
204	The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplantation, 2019, 54, 567-577.	1.3	19
205	Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study. Hematological Oncology, 2019, 37, 75-79.	0.8	7
206	Quantity and Quality Reconstitution of NKG2A+ Natural Killer Cells Are Associated with Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1-11.	2.0	24
207	Modification of donor lymphocyte infusion: how to improve the outcome?. Science China Life Sciences, 2019, 62, 1253-1256.	2.3	6
208	Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. BMC Medicine, 2019, 17, 156.	2.3	55
209	High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia. Cancer Medicine, 2019, 8, 5459-5467.	1.3	7
210	Myeloid-derived suppressor cells in hematological malignancies: friends or foes. Journal of Hematology and Oncology, 2019, 12, 105.	6.9	70
211	Update of the â€œBeijing Protocolâ€•haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 703-707.	1.3	28
212	Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. Journal of Hematology and Oncology, 2019, 12, 88.	6.9	76
213	Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. Journal of Hematology and Oncology, 2019, 12, 87.	6.9	24
214	The prognostic significance of Wilmsâ€™ tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia. Annals of Hematology, 2019, 98, 2551-2559.	0.8	8
215	Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia. Frontiers of Medicine, 2019, 13, 667-679.	1.5	2
216	Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1310-1318.	1.3	38

#	Article	IF	Citations
217	Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. American Journal of Hematology, 2019, 94, 512-521.	2.0	51
218	All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complementâ€“interleukin-1Î² loop. Haematologica, 2019, 104, 1661-1675.	1.7	25
219	Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. Bone Marrow Transplantation, 2019, 54, 1319-1326.	1.3	35
220	G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1419-1433.	1.3	40
221	Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 354-364.	1.5	8
222	FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplantation, 2019, 54, 1462-1470.	1.3	9
223	Donor selection for haploidentical hematopoietic cell transplantationâ€•practice guidance. Advances in Cell and Gene Therapy, 2019, 2, e42.	0.6	0
224	MAGE genes: Prognostic indicators in AL amyloidosis patients. Journal of Cellular and Molecular Medicine, 2019, 23, 5672-5678.	1.6	6
225	Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100Âdays after allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1877-1883.	0.8	20
226	Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation. Clinical Immunology, 2019, 205, 49-56.	1.4	6
227	Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Annals of Hematology, 2019, 98, 1627-1640.	0.8	14
228	Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1674-1681.	2.0	24
229	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1733-1742.	0.8	6
230	Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1629-1636.	2.0	6
231	Early myeloid-derived suppressor cells (HLA-DRâ¯/lowCD33+CD16â¯) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. Journal of Hematology and Oncology, 2019, 12, 31.	6.9	35
232	Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1694-1700.	1.3	9
233	S100A16 suppresses the growth and survival of leukaemia cellsÂand correlates with relapse and relapse free survival in adults with Philadelphia chromosomeâ€•negative Bâ€•cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 836-851.	1.2	7
234	Reduced Î²2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT. Science China Life Sciences, 2019, 62, 921-929.	2.3	2

#	Article	IF	Citations
235	Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 492-503.	1.5	5
236	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, 1210-1217.	2.0	2
237	Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. Leukemia and Lymphoma, 2019, 60, 2181-2189.	0.6	15
238	Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia. Blood Advances, 2019, 3, 1416-1428.	2.5	18
239	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Advances, 2019, 3, 1303-1317.	2.5	43
240	Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Advances, 2019, 3, 4312-4325.	2.5	27
241	Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. Blood Advances, 2019, 3, 3406-3418.	2.5	8
242	Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase. Scientific Reports, 2019, 9, 17601.	1.6	13
243	Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Frontiers in Immunology, 2019, 10, 2516.	2.2	36
244	Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy. Oncologist, 2019, 24, e1141-e1147.	1.9	14
245	Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Medicine (United States), 2019, 98, e18079.	0.4	7
246	Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma. Chinese Medical Journal, 2019, 132, 1765-1772.	0.9	4
247	Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. Science China Life Sciences, 2019, 62, 691-697.	2.3	16
248	Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety. Frontiers of Medicine, 2019, 13, 344-353.	1.5	5
249	Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft?. Seminars in Hematology, 2019, 56, 201-208.	1.8	10
250	A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. Platelets, 2019, 30, 994-1000.	1.1	10
251	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clinical Cancer Research, 2019, 25, 1737-1748.	3.2	26
252	Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course. British Journal of Haematology, 2019, 184, 788-796.	1.2	8

#	Article	IF	Citations
253	Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study. Frontiers of Medicine, 2019, 13, 365-377.	1.5	11
254	Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. Cancer, 2019, 125, 1499-1506.	2.0	17
255	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer Letters, 2019, 442, 193-201.	3.2	12
256	Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. Biology of Blood and Marrow Transplantation, 2019, 25, 1611-1620.	2.0	30
257	Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. Bone Marrow Transplantation, 2019, 54, 1198-1207.	1.3	12
258	Occurrence and Severity of Donor Lymphocyte Infusionâ€“Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 912-920.	2.0	4
259	Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 45-56.	1.5	26
260	Comments on the article: â€˜Donorâ€derived <scp>CD</scp>19â€targeted T cell infusion induces minimal residual diseaseâ€negative remission in relapsed Bâ€cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantationâ€™â€• Response to Pan etÂal. British Journal of Haematology, 2019, 184, 882-883.	1.2	0
261	Interferon-Î± salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 238-249.	1.5	18
262	Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis. Frontiers in Oncology, 2019, 9, 1513.	1.3	65
263	An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia. Blood, 2019, 134, 493-493.	0.6	24
264	ATRA Could Correct the Defective S1P-Mediated Cytoskeletal Reorganization in Proplatelet Formation of ITP. Blood, 2019, 134, 218-218.	0.6	1
265	The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis. Blood, 2019, 134, 2616-2616.	0.6	0
266	Haploidentical Hematopoietic Stem Cell Transplantation May Improve Prognosis in Non-Infant Children with t(v;11q23)/MLL-Rearranged B-Acute Lymphoblastic Leukemia. Blood, 2019, 134, 2049-2049.	0.6	0
267	Autophagy in Endothelial Cells Regulates Their Hematopoiesis Supporting Ability. Blood, 2019, 134, 4425-4425.	0.6	0
268	Effect of sorafenib on the outcomes of patients with FLT3â€ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Cancer, 2018, 124, 1954-1963.	2.0	51
269	The impact of donor characteristics on the invariant natural killer T cells of granulocyte-colony-stimulating factor-mobilized marrow grafts and peripheral blood grafts. Transplant Immunology, 2018, 48, 55-59.	0.6	3
270	Update on current research into haploidentical hematopoietic stem cell transplantation. Expert Review of Hematology, 2018, 11, 273-284.	1.0	20

#	Article	IF	Citations
271	Tâ€cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3â€ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2018, 93, 736-744.	2.0	21
272	Effect of the inÂvivo application of granulocyte colonyâ€stimulating factor on <scp>NK</scp> cells in bone marrow and peripheral blood. Journal of Cellular and Molecular Medicine, 2018, 22, 3025-3034.	1.6	15
273	Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses. Immunity, 2018, 48, 675-687.e7.	6.6	369
274	Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, openâ€label phase 3 study. Cancer Medicine, 2018, 7, 1043-1055.	1.3	32
275	Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT. Biology of Blood and Marrow Transplantation, 2018, 24, 1350-1359.	2.0	39
276	Nâ€acetylâ€Lâ€cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia postâ€allotransplant. British Journal of Haematology, 2018, 180, 863-878.	1.2	22
277	Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. Functional and Integrative Genomics, 2018, 18, 287-299.	1.4	15
278	Nâ€acetylâ€Lâ€cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2018, 93, 931-942.	2.0	29
279	Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Annals of Hematology, 2018, 97, 967-975.	0.8	27
280	Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL. Annals of Hematology, 2018, 97, 799-811.	0.8	0
281	Diminished expression of Î²2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. Annals of Hematology, 2018, 97, 641-654.	0.8	9
282	Inverse correlation of VÎ´2⁺ Tâ€cell recovery with <scp>EBV</scp> reactivation after haematopoietic stem cell transplantation. British Journal of Haematology, 2018, 180, 276-285.	1.2	23
283	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Annals of Hematology, 2018, 97, 485-495.	0.8	14
284	Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood, 2018, 131, 1219-1233.	0.6	40
285	Firstâ€line choice for severe aplastic anemia in children: Transplantation from a haploidentical donor vs immunosuppressive therapy. Clinical Transplantation, 2018, 32, e13179.	0.8	29
286	Acute kidney injury following haplo stem cell transplantation: incidence, risk factors and outcome. Bone Marrow Transplantation, 2018, 53, 483-486.	1.3	11
287	Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the <scp>TNFAIP</scp>3/<scp>NF</scp>â€ÎºB/<scp>SMAD</scp> pathway in patients with immune thrombocytopenia. British Journal of Haematology, 2018, 180, 395-411.	1.2	32
288	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2018, 53, 521-534.	1.3	168

#	Article	IF	Citations
289	Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2018, 53, 507-510.	1.3	4
290	Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 600-608.	1.3	9
291	Plerixafor and granulocyteâ€colonyâ€stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with nonâ^Hodgkin's lymphoma: a randomized Phase 3 study. Transfusion, 2018, 58, 81-87.	0.8	21
292	Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood, 2018, 131, 2987-2989.	0.6	36
293	The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in Chinaâ€"recommendations from the Chinese Society of Hematology. Journal of Hematology and Oncology, 2018, 11, 33.	6.9	233
294	The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2018, 97, 1547-1554.	0.8	15
295	IgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT. Annals of Hematology, 2018, 97, 1399-1406.	0.8	6
296	Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosomeâ€"Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1936-1943.	2.0	25
297	Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease. Science China Life Sciences, 2018, 61, 902-911.	2.3	14
298	T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clinical Immunology, 2018, 190, 32-40.	1.4	24
299	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. Science China Life Sciences, 2018, 61, 924-933.	2.3	1
300	Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids. Annals of Hematology, 2018, 97, 1209-1217.	0.8	10
301	Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia. Leukemia, 2018, 32, 2285-2287.	3.3	32
302	Monitoring of postâ€transplant <scp>CBFB</scp>â€<scp>MYH</scp>11 as minimal residual disease, rather than <scp>KIT</scp> mutations, can predict relapseÂafter allogeneic haematopoietic cell transplantation inÂadults with inv(16) acute myeloid leukaemia. British Journal of Haematology, 2018, 180, 448-451.	1.2	26
303	The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 967-972.	0.6	12
304	Homeostatic Î³Î´ T Cell Contents Are Preserved by Granulocyte Colony-Stimulating Factor Priming and Correlate with the Early Recovery of Î³Î´ T Cell Subsets after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 252-259.	2.0	12
305	Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 163-168.	2.0	6
306	The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Leukemia Research, 2018, 65, 14-19.	0.4	21

#	Article	IF	Citations
307	Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 741-750.	2.0	36
308	Thrombotic microangiopathy with concomitant <scp>GI</scp> aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. European Journal of Haematology, 2018, 100, 171-181.	1.1	13
309	Utility of flexible bronchoscopy with polymerase chain reaction in the diagnosis and management of pulmonary infiltrates in allogeneic <scp>HSCT</scp> patients. Clinical Transplantation, 2018, 32, e13146.	0.8	8
310	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. American Journal of Hematology, 2018, 93, 246-253.	2.0	52
311	Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Chinese Medical Journal, 2018, 131, 2808-2816.	0.9	7
312	Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia. Chinese Medical Journal, 2018, 131, 2185-2192.	0.9	5
313	Dendritic Cells Are Critical for the Activation and Expansion of VÎ2+ T Cells After Allogeneic Hematopoietic Transplantation. Frontiers in Immunology, 2018, 9, 2528.	2.2	10
314	Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Frontiers in Immunology, 2018, 9, 3041.	2.2	50
315	Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection After Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation. Clinical Infectious Diseases, 2018, 67, S162-S173.	2.9	36
316	Interferon-Î± Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. Oncologist, 2018, 23, 1349-1357.	1.9	17
317	The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Letters, 2018, 438, 63-75.	3.2	116
318	Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?. Leukemia Research, 2018, 73, 16-20.	0.4	13
319	The clinical features and prognosis of the monoclonal gammopathy undetermined significance: A single center study. Blood Cells, Molecules, and Diseases, 2018, 73, 9-13.	0.6	0
320	Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1866-1872.	2.0	1
321	An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2018, 182, 679-692.	1.2	36
322	Dysfunctional Bone Marrow Mesenchymal Stem Cells in Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1981-1989.	2.0	26
323	Achieving optimal response at 12Âmonths is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study. BMC Cancer, 2018, 18, 782.	1.1	13
324	A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype. Leukemia Research, 2018, 72, 12-19.	0.4	7

#	Article	IF	Citations
325	Prevalence and outcomes of uncommon <scp>BCR</scp>â€<scp>ABL</scp>1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. British Journal of Haematology, 2018, 182, 693-700.	1.2	31
326	Impairment of bone marrow endothelial progenitor cells in acute graftâ€versusâ€host disease patients after allotransplant. British Journal of Haematology, 2018, 182, 870-886.	1.2	15
327	Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis. Bone Marrow Transplantation, 2018, 53, 770-773.	1.3	18
328	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). Blood Cancer Journal, 2018, 8, 76.	2.8	21
329	Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 871-879.	5.1	110
330	Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study. Human Immunology, 2018, 79, 672-677.	1.2	11
331	Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance. Blood Cancer Journal, 2018, 8, 61.	2.8	10
332	High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. Medical Science Monitor, 2018, 24, 758-767.	0.5	17
333	Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China. Medical Science Monitor, 2018, 24, 5258-5270.	0.5	2
334	Hepatitis E Virus Infection after Haploidentical Hematopoietic Stem Cell Transplantation:Incidence and Clinical Course. Blood, 2018, 132, 5734-5734.	0.6	0
335	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Blood, 2018, 132, 3463-3463.	0.6	0
336	Haplo-SCT Mediates Stronger GVL Effect Than HLA-Matched Sibling Allograft By Significantly Reducing Leukemia Burden. Blood, 2018, 132, 2186-2186.	0.6	0
337	Influences of Mycophenolate Mofetil and Cyclosporine-a on the Ex Vivo-Expanded VÎ´2 T Cells. Blood, 2018, 132, 5686-5686.	0.6	0
338	Positive Stool Cultures Could Predict the Clinical Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 5757-5757.	0.6	0
339	Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?. Blood, 2018, 132, 2813-2813.	0.6	0
340	Poor NKG2C+ Adaptive NK Cell Recovery at Early Stage after Allo-HSCT Increased the Occurrence of Refractory Cytomegalovirus Infection. Blood, 2018, 132, 360-360.	0.6	0
341	Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements. Annals of Hematology, 2017, 96, 567-574.	0.8	19
342	Association between C-reactive protein levels in the first 1â€“3 days post-transplant and allogeneic immune reactions. Biomarkers in Medicine, 2017, 11, 117-124.	0.6	1

#	Article	IF	Citations
343	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 44.	6.9	51
344	Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. Journal of Hematology and Oncology, 2017, 10, 25.	6.9	151
345	Impact of ABO incompatibility on patientsâ€™ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica, 2017, 102, 1066-1074.	1.7	40
346	Viral encephalitis after haploâ€identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. European Journal of Haematology, 2017, 98, 450-458.	1.1	22
347	Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Diseaseâ€“Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 1311-1319.	2.0	66
348	IFN-Î± Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. Biology of Blood and Marrow Transplantation, 2017, 23, 1303-1310.	2.0	40
349	Recipientâ€donor KIR ligand matching prevents CMV reactivation postâ€haploidentical T cellâ€replete transplantation. British Journal of Haematology, 2017, 177, 766-781.	1.2	21
350	A Retrospective Study of Central Nervous System Invasive Fungal Disease after Allogeneic Stem Cell Transplantation: Risk Factors, Clinical Characteristics, and Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 1158-1164.	2.0	8
351	Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of postâ€transplantation minimal residual disease (<scp>MRD</scp>) monitoring and <scp>MRD</scp>â€directed intervention. British Journal of Haematology, 2017, 179, 184-197.	1.2	40
352	Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. Journal of Translational Medicine, 2017, 15, 57.	1.8	32
353	Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study. International Journal of Hematology, 2017, 106, 221-228.	0.7	6
354	Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 829-838.	0.8	39
355	Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 906-912.	2.0	25
356	Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Longâ€term outcomes of a prospective randomized trial. Cancer, 2017, 123, 2881-2892.	2.0	63
357	Donorâ€derived <scp>CD</scp>19â€targeted T cell infusion induces minimal residual diseaseâ€negative remission in relapsed Bâ€cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2017, 179, 598-605.	1.2	87
358	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. OncoImmunology, 2017, 6, e1356152.	2.1	28
359	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. Stem Cells and Development, 2017, 26, 1648-1661.	1.1	36
360	Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus. Journal of Infectious Diseases, 2017, 216, 945-956.	1.9	82

#	Article	IF	Citations
361	Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematology,the, 2017, 4, e487-e496.	2.2	38
362	Effects of preâ€•and postâ€†transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigenâ€•matched or mismatched related donor allografts. American Journal of Hematology, 2017, 92, E659-E661.	2.0	19
363	Haploidentical transplantation compared with matched siblingÂand unrelated donor transplantation for adults with standardâ€risk acute lymphoblastic leukaemia in first complete remission. British Journal of Haematology, 2017, 179, 120-130.	1.2	70
364	The clinical significance of monitoring the expression of the <scp>SIL</scp>â€<scp>TAL</scp>1 fusion gene in Tâ€cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. International Journal of Laboratory Hematology, 2017, 39, 613-619.	0.7	13
365	Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China. Clinical Therapeutics, 2017, 39, 1758-1768.	1.1	2
366	Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. Leukemia Research, 2017, 59, 136-141.	0.4	8
367	Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. Leukemia and Lymphoma, 2017, 58, 1384-1393.	0.6	3
368	The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Leukemia and Lymphoma, 2017, 58, 1135-1143.	0.6	27
369	The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group. Annals of Hematology, 2017, 96, 279-288.	0.8	8
370	Higher dose of <scp>CD</scp>34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients. Clinical Transplantation, 2017, 31, e12880.	0.8	4
371	Prognostic value of lactate dehydrogenase in Chinese patients with newly diagnosed transplant eligible multiple myeloma. Leukemia and Lymphoma, 2017, 58, 1740-1742.	0.6	4
372	Risk factors for herpes simplex virus-1/2 viremia and clinical outcomes following unmanipulated haploidentical haematopoietic stem cell transplantation. Journal of Clinical Virology, 2017, 95, 20-25.	1.6	10
373	Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL. Journal of Translational Medicine, 2017, 15, 184.	1.8	11
374	Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. Journal of Hematology and Oncology, 2017, 10, 134.	6.9	132
375	LncRNA H19 regulates ID2 expression through competitive binding to hsa-miR-19a/b in acute myelocytic leukemia. Molecular Medicine Reports, 2017, 16, 3687-3693.	1.1	47
376	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 2143-2150.	2.0	19
377	Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.. Journal of Clinical Oncology, 2017, 35, 7028-7028.	0.8	12
378	Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program. Annals of Transplantation, 2017, 22, 384-401.	0.5	15

#	Article	IF	Citations
379	CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia. Oncotarget, 2017, 8, 105397-105406.	0.8	10
380	Oral Arsenic Plus Retinoic Acid Versus Intravenous Arsenic Plus Retinoic Acid for Non-High Risk Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trials. Blood, 2017, 130, 641-641.	0.6	1
381	miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine- 2,3-dioxygenase. Oncotarget, 2016, 7, 48321-48334.	0.8	26
382	More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis. Drug Design, Development and Therapy, 2016, Volume 10, 3673-3679.	2.0	10
383	Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation. Journal of Thoracic Disease, 2016, 8, 2219-2225.	0.6	2
384	Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Journal of Hematology and Oncology, 2016, 9, 97.	6.9	20
385	Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. Clinical Transplantation, 2016, 30, 994-1001.	0.8	11
386	Haploidentical hematopoietic stem cell transplantation for paediatric highâ€risk <scp>T</scp>â€cell acute lymphoblastic leukaemia. Pediatric Transplantation, 2016, 20, 572-580.	0.5	8
387	Salvage chemotherapy followed by granulocyte colonyâ€stimulating factorâ€primed donor leukocyte infusion with graftâ€vs.â€host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. European Journal of Haematology, 2016, 96, 297-308.	1.1	37
388	GII.4 Sydney_2012 norovirus infection in immunocompromised patients in Beijing and its rapid evolution in vivo. Journal of Medical Virology, 2016, 88, 224-233.	2.5	11
389	High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation. European Journal of Haematology, 2016, 96, 517-526.	1.1	8
390	B-cell acute lymphoblastic leukemia associated with SET-NUP214 rearrangement: A case report and review of the literature. Oncology Letters, 2016, 11, 2644-2650.	0.8	18
391	Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood, 2016, 128, 2988-2999.	0.6	73
392	Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21). Leukemia Research, 2016, 44, 40-44.	0.4	29
393	Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1080-1086.	2.0	16
394	High-dose corticosteroid associated with catheter-related thrombosis after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 2016, 144, 6-11.	0.8	5
395	Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. Clinical Cancer Research, 2016, 22, 3467-3476.	3.2	142
396	Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia. Annals of Hematology, 2016, 95, 959-965.	0.8	18

#	Article	IF	Citations
397	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. Journal of Clinical Oncology, 2016, 34, 1855-1863.	0.8	100
398	Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. Biology of Blood and Marrow Transplantation, 2016, 22, 2235-2242.	2.0	11
399	Factors affecting the CD34+ cell yields from the second donations of healthy donors: The steady-state lymphocyte count is a good predictive factor. Transfusion and Apheresis Science, 2016, 55, 311-317.	0.5	2
400	Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression. Stem Cells Translational Medicine, 2016, 5, 1631-1643.	1.6	57
401	Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1637-1643.	0.8	27
402	Longâ€term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid. British Journal of Haematology, 2016, 174, 820-822.	1.2	22
403	Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia. Methods in Molecular Biology, 2016, 1465, 1-15.	0.4	7
404	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. OncoImmunology, 2016, 5, e1250992.	2.1	21
405	Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematology,the, 2016, 3, e581-e591.	2.2	34
406	Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. Journal of Hematology and Oncology, 2016, 9, 87.	6.9	57
407	Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. Journal of Infection, 2016, 73, 261-270.	1.7	19
408	Varying responses of PML-RARA with different genetic mutations to arsenic trioxide. Blood, 2016, 127, 243-250.	0.6	26
409	Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with highâ€risk acute lymphoblastic leukemia. International Journal of Cancer, 2016, 139, 2106-2115.	2.3	47
410	Haploâ€identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. British Journal of Haematology, 2016, 175, 265-274.	1.2	109
411	Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. Haematologica, 2016, 101, e352-e354.	1.7	49
412	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Chinese Journal of Cancer, 2016, 35, 46.	4.9	11
413	Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1233-1240.	0.8	16
414	Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1376-1382.	2.0	33

#	Article	IF	Citations
415	Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia. Leukemia Research, 2016, 47, 8-15.	0.4	7
416	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. Journal of Hematology and Oncology, 2016, 9, 35.	6.9	78
417	Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution. Clinical Transplantation, 2016, 30, 170-178.	0.8	11
418	Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation, 2016, 22, 23-26.	2.0	70
419	Increased prostacyclin levels inhibit the aggregation and activation of platelets via the PI3Kâ€“AKT pathway in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 2016, 139, 1-9.	0.8	8
420	Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation, 2016, 22, S15-S18.	2.0	47
421	Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. OncoImmunology, 2016, 5, e1139274.	2.1	24
422	Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Seminars in Hematology, 2016, 53, 82-89.	1.8	48
423	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leukemia and Lymphoma, 2016, 57, 2133-2139.	0.6	8
424	MiR-125a-5p decreases after long non-coding RNA HOTAIR knockdown to promote cancer cell apoptosis by releasing caspase 2. Cell Death and Disease, 2016, 7, e2137-e2137.	2.7	37
425	Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. Journal of Clinical Virology, 2016, 75, 10-15.	1.6	21
426	CD38+ CD58â˚' is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients. Leukemia Research, 2016, 43, 33-38.	0.4	16
427	Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China. Tumor Biology, 2016, 37, 7893-7900.	0.8	10
428	Helicobacter pyloriinfection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. Platelets, 2016, 27, 223-229.	1.1	7
429	Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study. Blood, 2016, 128, 1928-1928.	0.6	6
430	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience. Blood, 2016, 128, 2308-2308.	0.6	1
431	Aberrant TNFAIP3 Induces Mesenchymal Stem Cell Impairment Via the NF-Kb/SMAD7 Signaling Pathway in Immune Thrombocytopenia. Blood, 2016, 128, 364-364.	0.6	1
432	Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. Oncotarget, 2016, 7, 30892-30906.	0.8	48

#	Article	IF	Citations
433	Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 4602-4602.	0.6	0
434	Desialylation of Megakaryocytes Diminishes Platelet Production By Disrupting Megakaryocyte Adhesion, Migration and Proplatelet Formation in Chronic Immune Thrombocytopenia. Blood, 2016, 128, 165-165.	0.6	0
435	Polymorphisms of CTLA-4 Are Associated with Treatment Outcome in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens. Blood, 2016, 128, 3323-3323.	0.6	0
436	ADAM28 Enhanced the Growth and Dissemination of AML and Identified a Subgroup of AML Patients with a High Risk of Relapse in a Prospective Clinical Study. Blood, 2016, 128, 2902-2902.	0.6	0
437	Crucial Role of Complement Activation and IL-1Î² in Bone Marrow Niche of Immune Thrombocytopenia. Blood, 2016, 128, 166-166.	0.6	0
438	Evolving Criteria for Donor Selection for Transplants in Acute Myeloid Leukemia. Blood, 2016, 128, 5846-5846.	0.6	0
439	Association Between C-Reactive Protein in the First 1-3 Days Post-Transplant and Allogeneic Immune Reactions in Pediatric Haploidentical Stem Cell Transplantation. Blood, 2016, 128, 5794-5794.	0.6	0
440	Two Doses of Antithymocyteglobulin As Graft-Versus-Host Disease Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation: A Multicenter Prospective Study. Blood, 2016, 128, 4603-4603.	0.6	1
441	Dysfunction of Bone Marrow Endothelial Progenitor Cells from Subjects with Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation Can be Improved By Atorvastatin. Blood, 2016, 128, 3386-3386.	0.6	0
442	Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based Study. Blood, 2016, 128, 5439-5439.	0.6	1
443	The Real World of Arsenic Uses in Chinese with Acute Promyelocytic Leukemia: A Cross-Sectional Survey. Blood, 2016, 128, 5955-5955.	0.6	0
444	Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study. Advances in Therapy, 2015, 32, 1140-1159.	1.3	27
445	Fighting against hematological malignancy in China: from unique system to global impact. Science China Life Sciences, 2015, 58, 1183-1190.	2.3	11
446	Haploidentical stem cell transplantation in patients aged 50Âyr and older with leukemia: similar outcomes compared to younger adults. Clinical Transplantation, 2015, 29, 523-530.	0.8	14
447	Infusionâ€related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graftâ€versusâ€host disease. Pediatric Transplantation, 2015, 19, 918-924.	0.5	11
448	Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. Journal of Translational Medicine, 2015, 13, 391.	1.8	24
449	Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. Journal of Hematology and Oncology, 2015, 8, 116.	6.9	34
450	Recipient expression of ligands for donor inhibitory KIRs enhances NKâ€cell function to control leukemic relapse after haploidentical transplantation. European Journal of Immunology, 2015, 45, 2396-2408.	1.6	42

#	Article	IF	Citations
451	Lowâ€dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical <scp>HSCT</scp>. Clinical Transplantation, 2015, 29, 594-605.	0.8	16
452	Lateâ€onset Epsteinâ€“Barr virusâ€related disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation is associated with impaired early recovery of <scp>T</scp> and <scp>B</scp> lymphocytes. Clinical Transplantation, 2015, 29, 904-910.	0.8	4
453	Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors. Transfusion, 2015, 55, 2023-2031.	0.8	16
454	The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyteâ€“colonyâ€stimulating factorâ€“mobilized marrow harvests and peripheral blood harvests. Transfusion, 2015, 55, 2874-2881.	0.8	18
455	Outpatient Oral Treatment for Acute Promyelocytic Leukemia. New England Journal of Medicine, 2015, 372, 884-885.	13.9	13
456	The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?. Blood Reviews, 2015, 29, 205-213.	2.8	59
457	Interferon-Î±: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1939-1947.	2.0	56
458	Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study. Thrombosis Research, 2015, 135, 835-840.	0.8	3
459	Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes. Molecular Cancer, 2015, 14, 26.	7.9	27
460	Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood, 2015, 125, 3956-3962.	0.6	387
461	ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica, 2015, 100, 585-594.	1.7	38
462	Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: A multicenter prospective study of 2302 patients in China. Leukemia Research, 2015, 39, 530-535.	0.4	15
463	Haploidentical Hematopoietic Stem Cell Transplantation without InÂVitro T Cell Depletion for the Treatment of Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1110-1116.	2.0	44
464	Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation in China: A Multicenter Prospective Observational Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1117-1126.	2.0	81
465	Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. Leukemia Research, 2015, 39, 1319-1324.	0.4	24
466	ADAM28 overexpression regulated via the PI3K/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia. Leukemia Research, 2015, 39, 1229-1238.	0.4	15
467	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. Leukemia and Lymphoma, 2015, 56, 3116-3123.	0.6	31
468	IL-35 inhibits acute graft-versus-host disease in a mouse model. International Immunopharmacology, 2015, 29, 383-392.	1.7	11

#	Article	IF	Citations
469	Epstein-Barr Virusâ€“Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. Biology of Blood and Marrow Transplantation, 2015, 21, 2185-2191.	2.0	46
470	Pharmacokinetic Properties and Safety Profile of Histamine Dihydrochloride Injection in Chinese Healthy Volunteers: A Phase I, Single-center, Open-label, Randomized Study. Clinical Therapeutics, 2015, 37, 2352-2364.	1.1	6
471	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. Journal of Hematology and Oncology, 2015, 8, 84.	6.9	160
472	Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients. Blood, 2015, 126, 4247-4247.	0.6	1
473	Abnormalities of Bone Marrow Immune Micro-Environment in Patients with Immune Thrombocytopenia. Blood, 2015, 126, 3464-3464.	0.6	0
474	Treatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies. Oncology Letters, 2014, 7, 177-182.	0.8	15
475	Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center. Leukemia Research, 2014, 38, 1435-1440.	0.4	63
476	Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 440-449.	2.0	88
477	Association between an Impaired Bone Marrow Vascular Microenvironment and Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1190-1197.	2.0	49
478	Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemiaâ€“Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 929-936.	2.0	28
479	Total Body Irradiation and Cyclophosphamide Plus Antithymocyte Globulin Regimen Is Well Tolerated and Promotes Stable Engraftment as a Preparative Regimen before T Cellâ€“Replete Haploidentical Transplantation for Acute Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1176-1182.	2.0	21
480	Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy in Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 1314-1321.	2.0	36
481	Cytomegalovirus is a potential risk factor for lateâ€onset hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2014, 89, 55-61.	2.0	39
482	A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood, 2014, 124, 1645-1654.	0.6	232
483	Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). Journal of Hematology and Oncology, 2014, 7, 59.	6.9	56
484	Mesenchymal Stem Cells versus Mesenchymal Stem Cells Combined with Cord Blood for Engraftment Failure after Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective, Open-Label, Randomized Trial. Biology of Blood and Marrow Transplantation, 2014, 20, 236-242.	2.0	26
485	The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation. Clinical Transplantation, 2014, 28, 926-934.	0.8	5
486	Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood, 2014, 124, 843-850.	0.6	285

#	Article	IF	Citations
487	In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood, 2014, 124, 1880-1886.	0.6	106
488	Haplo-Identical Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Similar Survival in Comparison with HLA-Identical Siblings: Multi-Center, Prospective Study. Blood, 2014, 124, 1231-1231.	0.6	1
489	Hepatocyte Growth Factor Gene-Modified Adipose-Derived Mesenchymal Stem Cells Ameliorate Radiation Induced Liver Damage in a Rat Model. PLoS ONE, 2014, 9, e114670.	1.1	49
490	Prevalence and Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Comprehensive Large-Scale Study from a Single Chinese Center. Blood, 2014, 124, 1000-1000.	0.6	0
491	Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma. Chinese Medical Journal, 2014, 127, 1666-71.	0.9	4
492	Interferon Î±: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion. Chinese Medical Journal, 2014, 127, 2583-7.	0.9	14
493	Negative association of donor age with CD34â² cell dose in mixture allografts of G-CSF-primed bone marrow and G-CSF-mobilized peripheral blood harvests. Chinese Medical Journal, 2014, 127, 3597-601.	0.9	6
494	Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. Chinese Medical Journal, 2014, 127, 3602-9.	0.9	16
495	Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Annals of Hematology, 2013, 92, 1111-1119.	0.8	87
496	Longâ€term followâ€up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer, 2013, 119, 978-985.	2.0	224
497	PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes. Leukemia and Lymphoma, 2013, 54, 1442-1449.	0.6	23
498	Imaging and Pathological Findings of Solid Pseudopapillary Tumors of the Pancreas: A Report of 53 Cases. Practical Radiation Oncology, 2013, 3, S13-S14.	1.1	1
499	CT Findings, Clinicopathologic Features, and Treatment Modalities of Anorectal Melanoma: A Report of 10 Cases. Practical Radiation Oncology, 2013, 3, S14.	1.1	0
500	Improved outcomes using <scp>Gâ€CSF</scp>â€mobilized blood and bone marrow grafts as the source of stem cells compared with <scp>Gâ€PB</scp> after <scp>HLA</scp>â€identical sibling transplantation in patients with acute leukemia. Clinical Transplantation, 2013, 27, 844-851.	0.8	19
501	Haploidentical hematopoietic stem cell transplantation without in vitro T-cell-depletion for the treatment of hematologic diseases. Chimerism, 2013, 4, 26-28.	0.7	7
502	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood, 2013, 121, 4056-4062.	0.6	277
503	Intracranial Hemorrhage and Mortality In 1461 Patients After Allogeneic Hematopoietic Stem Cell Transplantation For 6-Year Follow-Up: Study Of 44 Cases. Blood, 2013, 122, 3322-3322.	0.6	12
504	Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia. Blood, 2013, 122, 1346-1346.	0.6	0

#	Article	IF	Citations
505	Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine and Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission. Blood, 2013, 122, 3290-3290.	0.6	0
506	Increased ADAM28 Levels In PlasmaÂand Bone Marrow CellsÂof Patients With Adult Acute Leukemia. Blood, 2013, 122, 4990-4990.	0.6	0
507	Philadelphia-Positive Leukemia Patients With The Y253H Or F359V Mutations Have a High Risk Of Developing New Mutations In The Setting Of Dasatinib Resistance. Blood, 2013, 122, 5188-5188.	0.6	0
508	A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy. Future Microbiology, 2012, 7, 201-209.	1.0	18
509	Risk stratificationâ€"directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood, 2012, 119, 3256-3262.	0.6	264
510	Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Micafungin versus Itraconazole for Prophylaxis of Invasive Fungal Infections in Patients undergoing Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2012, 18, 1509-1516.	2.0	72
511	The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood, 2012, 119, 5584-5590.	0.6	107
512	Immune Reconstitution Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation Compared with HLA-Identical Sibling Transplantation. Journal of Clinical Immunology, 2012, 32, 268-280.	2.0	81
513	Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2012, 91, 183-192.	0.8	103
514	Oral Realgar-Indigo Naturalis Formula Achieved Comparably High Rate of Remission and Survival to Intravenous Arsenic Trioxide As a Front-Line Treatment in Newly Diagnosed Acute Promyelocytic Leukemia: A Multi-Center Randomized Trial APL07. Blood, 2012, 120, 140-140.	0.6	1
515	CD34 Expression On the Blasts of Bone Marrow Is a Novel Predictor of Poor Prognosis Independent of FlT3-ITD in Acute Myeloid Leukemia with NPM1-Mutation.. Blood, 2012, 120, 2491-2491.	0.6	0
516	Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia. Blood, 2012, 120, 1433-1433.	0.6	0
517	A Clinical Study On Rituximab for Probable and Proven EBV Disease Post Haematopoietic Stem-Cell Transplantation. Blood, 2012, 120, 4512-4512.	0.6	0
518	Risk-Stratification Treatment Directed by Minimal Residual Disease Improves the Outcome of Acute Myeloid Leukemia with t(8;21) in First Complete Remission: Results of the AML05 Multicentre Trial. Blood, 2012, 120, 139-139.	0.6	1
519	Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. Best Practice and Research in Clinical Haematology, 2011, 24, 351-358.	0.7	9
520	Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 197-204.	2.0	58
521	Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2011, 17, 649-656.	2.0	11
522	Potential immunosuppressive function of plasma indoleamine 2,3â€dioxygenase in patients with aGVHD after alloâ€HSCT. Clinical Transplantation, 2011, 25, E304-11.	0.8	3

#	Article	IF	Citations
523	Contrasting the Long-Term Outcome of Reduced-Intensity Allogeneic Stem Cell Transplantation From Related Matched and Mismatched or Unrelated Matched Donor. Blood, 2011, 118, 2029-2029.	0.6	0
524	Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,. Blood, 2011, 118, 4161-4161.	0.6	0
525	Leukemia Initiating Cells: New Markers for Minimal Residual Disease Monitoring in B-Precursor Acute Lymphoblastic Leukemia. Blood, 2011, 118, 2528-2528.	0.6	0
526	Pre-Emptive Therapy with Modified Donor Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 659-659.	0.6	0
527	Hematopoietic stem cell transplantation in China: current status and prospects. American Journal of Blood Research, 2011, 1, 90-7.	0.6	8
528	Higher proportions of peripheral CD19+CD5+ B cells predict the effect of corticosteroid in patients with late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Chinese Medical Journal, 2011, 124, 1517-23.	0.9	5
529	Early Influence of Valve-Related Anticoagulation on False Lumen Thrombosis in Aortic Dissection Patients after Stented Elephant Trunk Surgery. Thoracic and Cardiovascular Surgeon, 2010, 58, 271-275.	0.4	9
530	Examination of copy number variations of CHST9 in multiple types of hematologic malignancies. Cancer Genetics and Cytogenetics, 2010, 203, 176-179.	1.0	15
531	HLA-mismatched/haploidentical hematopoietic stem cell transplantation: a field in which Chinese doctors are making great contributions. Chinese Medical Journal, 2010, 123, 1235-40.	0.9	8
532	Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. Annals of Hematology, 2009, 88, 159-166.	0.8	51
533	Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leukemia Research, 2009, 33, 384-390.	0.4	73
534	Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children. Biology of Blood and Marrow Transplantation, 2009, 15, 91-94.	2.0	28
535	Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 257-265.	2.0	278
536	Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia. Journal of Clinical Immunology, 2008, 28, 276-283.	2.0	66
537	Current status of haploidentical stem cell transplantation for leukemia. Journal of Hematology and Oncology, 2008, 1, 27.	6.9	47
538	Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2008, 14, 323-334.	2.0	72
539	Immune-related late-onset hemorrhagic cystitis post allogeneic hematopoietic stem cell transplantation. Chinese Medical Journal, 2008, 121, 1766-1769.	0.9	5
540	Immune-related late-onset hemorrhagic cystitis post allogeneic hematopoietic stem cell transplantation. Chinese Medical Journal, 2008, 121, 1766-9.	0.9	5

#	Article	IF	Citations
541	Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica, 2007, 92, 414-417.	1.7	147
542	Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versus-host disease. Chinese Medical Journal, 2007, 120, 1666-1671.	0.9	34
543	Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versus-host disease. Chinese Medical Journal, 2007, 120, 1666-71.	0.9	10
544	Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood, 2006, 107, 3065-3073.	0.6	482
545	Potentiating effects of L-type Ca2+ channel blockers on pentobarbital-induced hypnosis are influenced by serotonergic system. Journal of Neural Transmission, 2006, 113, 1395-1402.	1.4	10
546	An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chinese Medical Journal, 2003, 116, 736-41.	0.9	14
547	A CTLA-4 gene polymorphism at position â˜318 in the promoter region affects the expression of protein. Genes and Immunity, 2002, 3, 233-234.	2.2	173
548	Plasma Soluble Fas Ligand Levels in Hemopathic Patients Undergoing Allogeneic Bone Marrow Transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi / Zhongguo Bing Li Sheng Li Xue Hui = Journal of Experimental Hematology / Chinese Association of Pathophysiology, 2001, 9, 247-250.	0.2	0
549	Abrupt reduction of c-myc expression by antisense RNA inducing terminal differentiation and apoptosis of a human esophageal cancer cell line. Science in China Series B, Chemistry, Life Sciences & Earth Sciences, 1995, 38, 580-9.	0.0	0
550	Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment. Frontiers in Immunology, 0, 13, .	2.2	3
551	Donor CSF3R with the rs3917980A/G or G/G genotype is correlated with better leukemia-free survival after allogenic hematopoietic stem cell transplantation. Genes and Immunity, 0, , .	2.2	0